Malignant Melanoma | Unmet Need | US/EU | 2016

Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.

Login to access report

launch Related Market Assessment Reports